April 23, 2014 9:41 PM ET

Pharmaceuticals

Company Overview of Quinnova Pharmaceuticals, Inc.

Company Overview

Quinnova Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercial sale of prescription drug products based on dermal drug delivery platforms. It offers HYDRO 40 foam, a dry skin treatment product; tersi foam, a leave-on foam indicated for the treatment of seborrheic dermatitis and tinea versicolor; rinnovi nail system, a prescription nail system that is designed to clean, treat, and protect diseased, damaged, brittle, and ingrown nails; cleanse and treat, a pad delivery technology system for the treatment of acne; and Neosalus Lotion, a non-steroidal anti-inflammatory prescription product that offers topical treatment for the management of skin dis...

411 South State Street

3rd Floor

Newtown, PA 18940

United States

Founded in 2003

Phone:

215-860-6263

Fax:

215-860-6265

Key Executives for Quinnova Pharmaceuticals, Inc.

Co-founder
Co-Founder
Age: 42
Vice President of Finance
Vice President of Sales
Director and Executive Vice President of Safeguard Scientifics Inc
Age: 50
Compensation as of Fiscal Year 2013.

Quinnova Pharmaceuticals, Inc. Key Developments

Quinnova Pharmaceuticals LLC Announces Launch of ECOZA(TM) Topical Foam, 1%

Quinnova Pharmaceuticals LLC announced the launch of its recently U.S. Food and Drug Administration approved ECOZA(TM) (econazole nitrate) topical foam, 1%. ECOZA(TM) FOAM is indicated for the treatment of interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum in patients 12 years of age and older. ECOZA(TM) FOAM, a novel alternative for the treatment of interdigital tinea pedis (athletes foot between the toes), combines the proven antifungal efficacy of econazole nitrate with the skin-restoring properties of Proderm Technology(R). Proven to kill fungi that cause interdigital tinea pedis when applied once-daily for 4 weeks, its unique, alcohol-free foam delivery helps protect and restore skin, penetrating quickly and drying rapidly without the greasy residue that is common among other creams and gels. ECOZA(TM) FOAM is a prescription medicine used on the skin (topical) to treat athlete's foot that is between the toes (interdigital tinea pedis) in people 12 years of age and older. ECOZA(TM) FOAM should be applied to cover affected areas once daily for 4 weeks. ECOZA(TM) FOAM is for topical use only and is not for oral, ophthalmic, or intravaginal use. In two double-blind, parallel-group, vehicle-controlled, multicenter clinical trials, 495 subjects aged >=12 years with a clinical diagnosis of interdigital tinea pedis and fungal culture positive for a dermatophyte at baseline received ECOZA(TM) FOAM (n=246) or foam vehicle (n=249). Subjects applied ECOZA(TM) FOAM or foam vehicle once-daily for 4 weeks. The primary endpoint was proportion of subjects who achieved a complete cure (negative KOH, negative fungal culture, no evidence of clinical disease as indicated by complete resolution of all signs and symptoms) at 2 weeks post-treatment (Day 43). Secondary endpoints included mycologic cure (negative KOH and negative culture) and effective treatment (mycologic cure + no or mild erythema and/or scaling and all other signs and symptoms absent). The results from the clinical studies demonstrated that ECOZA(TM) FOAM exhibited superiority over foam vehicle for the primary and secondary endpoints and demonstrated potent antifungal activity against all of the pathogens evaluated with a high mycologic cure rate. The complete cure rate at Day 43 (2 weeks post-treatment) was higher in the ECOZA(TM) FOAM group (24.3%) than in the foam vehicle group (3.6%). In addition, higher rates of mycologic cure (67.6% vs 16.9%) and effective treatment (48.6% vs 10.8%) were observed with econazole nitrate foam 1% vs the foam vehicle. ECOZA(TM) FOAM was safe and well tolerated with a safety profile comparable with the foam vehicle. During clinical trials with ECOZA(TM) FOAM the most common adverse reactions were application site reactions, which occurred in less than 1% of subjects in both the ECOZA(TM) FOAM and vehicle arms. Click for full prescribing information.

Suneva Medical, Inc. Selects Quinnova Pharmaceuticals LLC to Co-Promote ReFissa

Suneva Medical, Inc. announced that it has selected Quinnova Pharmaceuticals, LLC to co-promote ReFissa. ReFissa is the FDA approved 0.05% tretinoin emollient cream indicated for the treatment of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin. The relationship will expand the awareness and prescriber base of ReFissa in the U.S. dermatology community.

Similar Private Companies By Industry

Company Name Region
Chakshu Research, Inc. United States
Androclus Therapeutics, Inc. United States
Visionary Therapeutics Corporation United States
Quanticel Pharmaceuticals, Inc. United States
ReProtect Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
December 16, 2013
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Quinnova Pharmaceuticals, Inc., please visit www.quinnova.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.